Briacell Therapeutics
BCTX
15 hedge funds and large institutions have $181K invested in Briacell Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 2 closing their positions.
488% more capital inflows, than outflows
Capital inflows: $158K | Capital outflows: $26.8K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
15% more funds holding
Funds holding: 13 → 15 (+2)
0.19% more ownership
Funds ownership: 0.14% → 0.33% (+0.19%)
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$144K |
| 2 |
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$12.8K |
| 3 |
Raymond James Financial
St Petersburg,
Florida
|
+$365 |
| 4 |
Allworth Financial
Folsom,
California
|
+$255 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$255 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$14K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$8.09K |
| 3 |
Morgan Stanley
New York
|
-$2.11K |
| 4 |
Concord Wealth Partners
Abingdon,
Virginia
|
-$1.22K |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$1.06K |
BCTX Hedge Fund Activity: Q2 2025 in Review
15 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q2 2025, worth a combined $181K — up 92% from $94.1K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BCTX positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 5 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $144K. The largest seller was UBS Group, cutting an estimated $14K.
- 15 institutional investors held Briacell Therapeutics (BCTX) as of Q2 2025, up from 13 in Q1 2025.
- Funds reported $181K of Briacell Therapeutics stock for Q2 2025, up 92% quarter-over-quarter.
- 4 funds opened new Briacell Therapeutics positions in Q2 2025 and 2 closed out, a net change of +2 holders.
- The largest Briacell Therapeutics buyer in Q2 2025 was Sabby Management, an estimated $144K added.
- The largest Briacell Therapeutics seller in Q2 2025 was UBS Group, an estimated $14K sold.
Based on aggregated 13F filings for Q2 2025.